| Use of basiliximab with mycophenolate mofetil in kidney transplantation. | |
| | |
MedLine Citation:
|
PMID: 14697927 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: Randomized, placebo-controlled studies have determined that administration of basiliximab (chimeric IL-2 receptor antagonist) decreases the acute rejection rate in kidney transplantation when used in combination with cyclosporine, azathioprine, and steroids. We report our experience using basiliximab with mycophenolate mofetil, a calcineurin inhibitor, and steroids in kidney transplantation. METHODS: We retrospectively analyzed 127 patients who received their first kidney transplant between September 1, 1998, and December 30, 2000, including 59 who received basiliximab (22 living and 37 cadaveric donor recipients) and the 68 that did not receive this antibody (31 living and 37 cadaveric donor recipients). The groups were demographically comparable for risk factors such as race, peak of panel-reactive antibody, delayed graft function, donor age, and cold ischemia time. The analysis assessed serum creatinine levels, acute rejection, cytomegalovirus infection, and posttransplant lymphoproliferative disease incidence as well as patient and graft survival at 6 months. RESULTS: Serum creatinine levels were 3 +/- 3.1 and 2.6 +/- 2.5 mg/dL (P =.346) at discharge, 1.5 +/- 0.6 and 1.7 +/- 1.1 mg/dL (P =.098) at 1 month, and 1.5 +/- 0.7 and 1.6 +/- 0.7 mg/dL (P =.454) at 6 months posttransplantation for patients treated with versus without basiliximab, respectively. Only one episode of acute rejection was seen among patients treated with basiliximab within 1 month posttransplantation versus three episodes among patients treated without basiliximab (P =.382). Three patients (5.1%) treated with basiliximab and two patients (2.9%) treated without basiliximab developed acute rejection within 6 months posttransplantation (P =.536). Patient and graft survivals at 6 months posttransplantation were not significantly different between patients treated with versus without basiliximab (100% and 100% versus 100% and 98.3%, respectively). There was no increased incidence of cytomegalovirus infection with the use of basiliximab (5.1% vs 5.9%, P =.844). There was only one case of posttransplant lymphoproliferative disease within 6 months posttransplantation in a patient treated without basiliximab. CONCLUSION: These data suggest that the routine addition of basiliximab to a mycophenolate mofetil-based regimens does not appear to be warranted. A larger prospective randomized study with longer follow-up is needed to confirm these results. |
| | |
Authors:
|
P W Baron; J Weissman; O N Ojogho; S Sahney; D Cutler; S James; C Oculam; F Abdelhalim; S L Nehlsen-Cannarella; S Teichman; W Concepcion |
Related Documents
:
|
3538547 - Renal transplantation in 45 patients with amyloidosis. 11793077 - Kidney transplantation in young children: should there be a minimum age? 19775317 - The impact of preexisting or acquired kaposi sarcoma herpesvirus infection in kidney tr... 10852597 - Double versus single renal allografts from aged donors. 9083287 - Prediction of left ventricular mass changes after renal transplantation by polymorphism... 21511097 - Alternatives to lung transplantation: lung volume reduction for copd. |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Transplantation proceedings Volume: 35 ISSN: 0041-1345 ISO Abbreviation: Transplant. Proc. Publication Date: 2003 Dec |
Date Detail:
|
Created Date: 2003-12-30 Completed Date: 2004-08-18 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0243532 Medline TA: Transplant Proc Country: United States |
Other Details:
|
Languages: eng Pagination: 2881-4 Citation Subset: IM |
Affiliation:
|
Loma Linda University Medical Center, 11234 Anderson Street Room 1405, Loma Linda, CA 92354, USA. pbaron@ahs.ilumc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antibodies, Monoclonal / therapeutic use* Cadaver Continental Population Groups Creatinine / blood Drug Therapy, Combination Female Follow-Up Studies Humans Immunosuppressive Agents / therapeutic use Kidney Transplantation / physiology* Length of Stay Living Donors Male Medical Records Mycophenolic Acid / analogs & derivatives*, therapeutic use* Recombinant Fusion Proteins* Retrospective Studies Time Factors Tissue Donors |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunosuppressive Agents; 0/Recombinant Fusion Proteins; 0/basiliximab; 128794-94-5/mycophenolate mofetil; 24280-93-1/Mycophenolic Acid; 60-27-5/Creatinine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejec...
Next Document: Influence of 1,25-dihydroxyvitamin D3 as an immunomodulator in renal transplant recipients: a retros...